Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient's body to target CD20-expressing malignant B cells PHILADELPHIA, Oct.

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

given the multitude of vaccine approaches currently being tested and the even greater number of vaccine target antigens being evaluated. In a recent report by the National Cancer Institute ...

Utilizing an analytic hierarchy process (AHP) based on preidentified criteria and weighted by a panel of experts, Cheever and colleagues constructed priority rankings of 75 cancer antigens.

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

The Ludwig Institute for Cancer Research (LICR) maintains the "CTDatabase." [4] This database is an authoritative list of known CT antigens. It also serves as a repository into which new candidates ...

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple ...

Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...

A new study published in the Journal of American Medical Association showed that the combination of testing for H pylori ...